Catalyst
Slingshot members are tracking this event:
Keryx (KERX) Plans to Submit FDA Application in Q3 to Expand Indication for Auryxia to Include the Treatment of Iron Deficiency Anemia in Adults With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KERX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 12, 2017
Occurred Source:
http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-newsArticle&ID=2237138
Related Projects
Related Keywords
Expanded Indication, Auryxia, Q3, Iron Deficiency Anemia, Stage 3-5, Non-dialysis-dependent, Chronic Kidney Disease, Fda Application
